The INVOKE clinical trial

The INVOKE study (OKN-4395-121) is a global, multicenter, Phase 1a/1b, first-in-human, open-label trial evaluating OKN4395 in patients with advanced solid tumors.

Clinical trial explainer

Play
Video
AI-powered study design
[
01:15
]
Description goes here
The INVOKE study schemaThe INVOKE study schema
Phase 1a focuses on dose escalation of OKN4395 as both a monotherapy and in combination with pembrolizumab. Phase 1b will expand into a further four cohorts.
The INVOKE study (OKN-4395-121; NCT06789172) is sponsored by Epkin (an affiliate of Owkin France).
BOIN = Bayesian Optimal Interval; SOCres = resistant to standard of care; n = number of participants; OBD = optimal biological dose; MTD = maximum tolerated dose; DLT = dose-limiting toxicity; PK = Pharmacokinetics;  1L/2L/3L = first/second/third line; SARC = Sarcoma; aPD1 ref/res = anti-PD1 refractory or resistant; NSCLC = Non-small cell lung cancer; MESO = Mesothelioma; HNSCC= Head & Neck squamous-cell carcinoma; R = randomized; ORR = Overall Response Rate.